NCT07120776View on ClinicalTrials.gov

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

September 30, 2027

Conditions
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)Left Ventricular Outflow Tract ObstructionMyocardial Ischaemia
Interventions
DRUG

Camzyos (Mavacamten)

Camzyos (Mavacamten), a selective cardiac myosin inhibitor prescribed as part of routine care in patients with symptomatic HOCM. The study evaluates its effect on myocardial perfusion over a 12-month period using PET-CT imaging.

Trial Locations (1)

M13 9WL

Manchester University NHS Foundation Trust, Manchester

All Listed Sponsors
lead

University of Manchester

OTHER

NCT07120776 - Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial | Biotech Hunter | Biotech Hunter